Literature DB >> 15578223

The USH1C 216G-->A splice-site mutation results in a 35-base-pair deletion.

Jennifer Lentz1, Sevtap Savas, San-San Ng, Grace Athas, Prescott Deininger, Bronya Keats.   

Abstract

Usher syndrome is characterized by profound hearing loss and retinal degeneration. A splice-site mutation, 216G-->A, in exon 3 of USH1C is associated with Acadian Usher type IC. This mutation was reported to create an in-frame deletion of 39 base pairs (bp), resulting in an unstable transcript. By RT-PCR analysis of 216A and 216G constructs transfected into HeLa cells and also of patient cell lines, we have demonstrated a frame-shift deletion of 35 bp, not 39 bp. Thus, the instability of the USH1C mRNA is explained by the 216G-->A out-of-frame splice site mutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15578223     DOI: 10.1007/s00439-004-1217-4

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  6 in total

1.  Structure, diversity, and evolution of the 45-bp VNTR in intron 5 of the USH1C gene.

Authors:  Sevtap Savas; Ben Frischhertz; Mark A Batzer; Prescott L Deininger; Bronya J B Keats
Journal:  Genomics       Date:  2004-03       Impact factor: 5.736

2.  Tightly linked flanking microsatellite markers for the Usher syndrome type I locus on the short arm of chromosome 11.

Authors:  B J Keats; N Nouri; M Z Pelias; P L Deininger; M Litt
Journal:  Am J Hum Genet       Date:  1994-04       Impact factor: 11.025

3.  A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene.

Authors:  M Bitner-Glindzicz; K J Lindley; P Rutland; D Blaydon; V V Smith; P J Milla; K Hussain; J Furth-Lavi; K E Cosgrove; R M Shepherd; P D Barnes; R E O'Brien; P A Farndon; J Sowden; X Z Liu; M J Scanlan; S Malcolm; M J Dunne; A Aynsley-Green; B Glaser
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C.

Authors:  E Verpy; M Leibovici; I Zwaenepoel; X Z Liu; A Gal; N Salem; A Mansour; S Blanchard; I Kobayashi; B J Keats; R Slim; C Petit
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

5.  The USH1C 216G-->A mutation and the 9-repeat VNTR(t,t) allele are in complete linkage disequilibrium in the Acadian population.

Authors:  Sevtap Savas; Ben Frischhertz; Mary Z Pelias; Mark A Batzer; Prescott L Deininger; Bronya B Keats
Journal:  Hum Genet       Date:  2001-12-06       Impact factor: 4.132

6.  Localization of two genes for Usher syndrome type I to chromosome 11.

Authors:  R J Smith; E C Lee; W J Kimberling; S P Daiger; M Z Pelias; B J Keats; M Jay; A Bird; W Reardon; M Guest
Journal:  Genomics       Date:  1992-12       Impact factor: 5.736

  6 in total
  12 in total

1.  Rescue of peripheral vestibular function in Usher syndrome mice using a splice-switching antisense oligonucleotide.

Authors:  Sarath Vijayakumar; Frederic F Depreux; Francine M Jodelka; Jennifer J Lentz; Frank Rigo; Timothy A Jones; Michelle L Hastings
Journal:  Hum Mol Genet       Date:  2017-09-15       Impact factor: 6.150

2.  Deafness and retinal degeneration in a novel USH1C knock-in mouse model.

Authors:  Jennifer J Lentz; William C Gordon; Hamilton E Farris; Glen H MacDonald; Dale E Cunningham; Carol A Robbins; Bruce L Tempel; Nicolas G Bazan; Edwin W Rubel; Elizabeth C Oesterle; Bronya J Keats
Journal:  Dev Neurobiol       Date:  2010-03       Impact factor: 3.964

Review 3.  New molecular therapies for the treatment of hearing loss.

Authors:  Yutian Ma; Andrew K Wise; Robert K Shepherd; Rachael T Richardson
Journal:  Pharmacol Ther       Date:  2019-05-08       Impact factor: 12.310

4.  Deafblindness in French Canadians from Quebec: a predominant founder mutation in the USH1C gene provides the first genetic link with the Acadian population.

Authors:  Inga Ebermann; Irma Lopez; Maria Bitner-Glindzicz; Carolyn Brown; Robert Karel Koenekoop; Hanno Jörn Bolz
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

Review 5.  Splicing modulation therapy in the treatment of genetic diseases.

Authors:  Virginia Arechavala-Gomeza; Bernard Khoo; Annemieke Aartsma-Rus
Journal:  Appl Clin Genet       Date:  2014-12-04

6.  Delayed diagnosis of a patient with Usher syndrome 1C in a Louisiana Acadian family highlights the necessity of timely genetic testing for the diagnosis and management of congenital hearing loss.

Authors:  Ayesha Umrigar; Amanda Musso; Danielle Mercer; Annette Hurley; Cassondra Glausier; Mona Bakeer; Michael Marble; Chindo Hicks; Fern Tsien
Journal:  SAGE Open Med Case Rep       Date:  2017-12-11

7.  Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c.

Authors:  Bifeng Pan; Charles Askew; Alice Galvin; Selena Heman-Ackah; Yukako Asai; Artur A Indzhykulian; Francine M Jodelka; Michelle L Hastings; Jennifer J Lentz; Luk H Vandenberghe; Jeffrey R Holt; Gwenaëlle S Géléoc
Journal:  Nat Biotechnol       Date:  2017-02-06       Impact factor: 54.908

8.  Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness.

Authors:  Jennifer J Lentz; Francine M Jodelka; Anthony J Hinrich; Kate E McCaffrey; Hamilton E Farris; Matthew J Spalitta; Nicolas G Bazan; Dominik M Duelli; Frank Rigo; Michelle L Hastings
Journal:  Nat Med       Date:  2013-02-04       Impact factor: 53.440

9.  Rescue of Outer Hair Cells with Antisense Oligonucleotides in Usher Mice Is Dependent on Age of Treatment.

Authors:  Abhilash Ponnath; Frederic F Depreux; Francine M Jodelka; Frank Rigo; Hamilton E Farris; Michelle L Hastings; Jennifer J Lentz
Journal:  J Assoc Res Otolaryngol       Date:  2017-10-12

Review 10.  rAAV-Mediated Cochlear Gene Therapy: Prospects and Challenges for Clinical Application.

Authors:  Fabian Blanc; Michel Mondain; Alexis-Pierre Bemelmans; Corentin Affortit; Jean-Luc Puel; Jing Wang
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.